Abstract: Compounds of this formula are useful for preventing breast cancer.

Abstract: A method for repairing a gas turbine stationary flowpath shroud. The method comprises providing a superalloy gas turbine stationary flowpath shroud that has previously been in service. The method further comprises preparing a restoration coating for application to the flowpath surface of the shroud by the steps of providing a precursor mixture comprising a higher-melting-point alloy component, a lower-melting-point alloy component, and a fugitive binder. A perform is prepared from the components and pre-sintered into a mildly curved form. The partially densified perform is applied to the flowpath surface and thermally bonded to the flowpath surface, forming a restoration coating.

Abstract: A method for repairing a gas turbine stationary flowpath shroud. The method comprises providing a superalloy gas turbine stationary flowpath shroud that has previously been in service. The method further comprises preparing a restoration coating for application to the flowpath surface of the shroud by the steps of providing a precursor mixture comprising a higher-melting-point alloy component, a lower-melting-point alloy component, and a fugitive binder. A perform is prepared from the components and pre-sintered into a mildly curved form. The partially densified perform is applied to the flowpath surface and thermally bonded to the flowpath surface, forming a restoration coating.

Abstract: A method of producing a puck for coating a turbine shroud includes: providing a mixture of a metallic powder and a binder; melting the mixture and forming the mixture into a preform having a shape conforming to the flowpath surface of the shroud; removing a majority of the binder from the preform; and heating the preform with microwave energy to remove the remainder of the binder and to sinter the metal powder together to form the puck. A turbine shroud may be repaired by bonding the puck to its flowpath surface.

Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein

Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.

Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.

Abstract: This invention relates to compounds useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, and to pharmaceutical composition, methods, and kits comprising such compounds.

Abstract: This invention relates to compounds useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, and to pharmaceutical composition, methods, and kits comprising such compounds.

Abstract: This invention relates to compounds useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, and to pharmaceutical composition, methods, and kits comprising such compounds.

Abstract: Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT2 receptors in animals are described herein.

Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Abstract: This invention provides compounds of formula I and pharmaceutically-acceptable salts thereof, where the substituents are defined in the specification, which are growth hormone secretogogues useful for treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength , mobility, maintenance of skin thickness, metabolic homeostatis or renal homeostasis. Compounds of formula I in combination with: a bisphosphonate such as alendronate; estrogen, estrogens, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions thereof are useful in treating osteoporosis.

Abstract: Compounds of this formula 1

Abstract: Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.

Abstract: This invention is directed to compounds of the formula 1

Abstract: This invention relates to compounds useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, and to pharmaceutical composition, methods, and kits comprising such compounds.

Abstract: Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.